Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cannabinoid–dopamine interactions in the physiology and physiopathology of the basal ganglia
Concepción García, Cristina Palomo‐Garo, Yolanda Gómez‐Gálvez, et al.
British Journal of Pharmacology (2015) Vol. 173, Iss. 13, pp. 2069-2079
Open Access | Times Cited: 94

Showing 1-25 of 94 citing articles:

Dopamine and Addiction
Roy A. Wise, Mykel A. Robble
Annual Review of Psychology (2020) Vol. 71, Iss. 1, pp. 79-106
Open Access | Times Cited: 301
Levodopa‐induced dyskinesia in Parkinson disease: Current and evolving concepts
Alberto J. Espay, Francesca Morgante, Aristide Merola, et al.
Annals of Neurology (2018) Vol. 84, Iss. 6, pp. 797-811
Open Access | Times Cited: 283
Endocannabinoid modulation of dopamine neurotransmission
Dan P. Covey, Yolanda Mateo, David Sulzer, et al.
Neuropharmacology (2017) Vol. 124, pp. 52-61
Open Access | Times Cited: 154
Focus on cannabinoids and synthetic cannabinoids
Reynald Le Boisselier, João Alexandre, Véronique Lelong‐Boulouard, et al.
Clinical Pharmacology & Therapeutics (2016) Vol. 101, Iss. 2, pp. 220-229
Closed Access | Times Cited: 150
Targeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders
Gemma Navarro, Paula Morales, Carmen Rodríguez‐Cueto, et al.
Frontiers in Neuroscience (2016) Vol. 10
Open Access | Times Cited: 134
Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson’s Disease
Felipe Patricio, Alan Axel Morales-Andrade, Aleidy Patricio-Martínez, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 97
Therapeutic applicability of cannabidiol and other phytocannabinoids in epilepsy, multiple sclerosis and Parkinson's disease and in comorbidity with psychiatric disorders
Maria de Fátima dos Santos Sampaio, Yara Bezerra de Paiva, Tuane Bazanella Sampaio, et al.
Basic & Clinical Pharmacology & Toxicology (2024) Vol. 134, Iss. 5, pp. 574-601
Open Access | Times Cited: 12
Subcellular specificity of cannabinoid effects in striatonigral circuits
Edgar Soria‐Gómez, Antonio C. Pagano Zottola, Yamuna Mariani, et al.
Neuron (2021) Vol. 109, Iss. 9, pp. 1513-1526.e11
Open Access | Times Cited: 43
Cerebrospinal fluid endocannabinoid levels in Gilles de la Tourette syndrome
Kirsten Müller‐Vahl, Laura Bîndilă, Beat Lutz, et al.
Neuropsychopharmacology (2020) Vol. 45, Iss. 8, pp. 1323-1329
Open Access | Times Cited: 49
Circadian clock organization in the retina: From clock components to rod and cone pathways and visual function
Jacob D. Bhoi, Manvi Goel, Christophe Ribelayga, et al.
Progress in Retinal and Eye Research (2022) Vol. 94, pp. 101119-101119
Open Access | Times Cited: 25
Endocannabinoid Modulation in Neurodegenerative Diseases: In Pursuit of Certainty
Alexandru Vasincu, Răzvan-Nicolae Rusu, Daniela Carmen Ababei, et al.
Biology (2022) Vol. 11, Iss. 3, pp. 440-440
Open Access | Times Cited: 24
Crosstalk between the endocannabinoid and mid-brain dopaminergic systems: Implication in dopamine dysregulation
Berhanu Geresu Kibret, Ana Canseco-Alba, Emmanuel S. Onaivi, et al.
Frontiers in Behavioral Neuroscience (2023) Vol. 17
Open Access | Times Cited: 14
Contrasting effects of selective MAGL and FAAH inhibition on dopamine depletion and GDNF expression in a chronic MPTP mouse model of Parkinson's disease
Noemi Pasquarelli, Christoph Porazik, Hanna Bayer, et al.
Neurochemistry International (2017) Vol. 110, pp. 14-24
Closed Access | Times Cited: 40
Can therapeutic strategies prevent and manage dyskinesia in Parkinson’s disease? An update
Valentina Leta, Peter Jenner, К. Ray Chaudhuri, et al.
Expert Opinion on Drug Safety (2019) Vol. 18, Iss. 12, pp. 1203-1218
Closed Access | Times Cited: 34
Medical cannabis as an alternative therapeutics for Parkinsons’ disease: Systematic review
Anastasia Bougea, Christos Koros, Athina‐Maria Simitsi, et al.
Complementary Therapies in Clinical Practice (2020) Vol. 39, pp. 101154-101154
Closed Access | Times Cited: 30
Endocannabinoid signaling in the central nervous system
César E. Martinez Ramirez, Gonzalo Ruiz‐Pérez, Todd M. Stollenwerk, et al.
Glia (2022) Vol. 71, Iss. 1, pp. 5-35
Open Access | Times Cited: 18
A journey through cannabidiol in Parkinson’s disease
Elaine Aparecida Del Bel, Nubia Barros-Pereira, Rafaela Ponciano de Moraes, et al.
International review of neurobiology (2024), pp. 65-93
Closed Access | Times Cited: 3
Cannabis and Cannabinoid Signaling: Research Gaps and Opportunities
Rita J. Valentino, Nora D. Volkow
Journal of Pharmacology and Experimental Therapeutics (2024) Vol. 391, Iss. 2, pp. 154-158
Open Access | Times Cited: 3
Brain region specific regulation of anandamide (down) and sphingosine-1-phosphate (up) in association with anxiety (AEA) and resilience (S1P) in a mouse model of chronic unpredictable mild stress
Caroline Fischer, Dominique Thomas, Robert Gurke, et al.
Pflügers Archiv - European Journal of Physiology (2024) Vol. 476, Iss. 12, pp. 1863-1880
Open Access | Times Cited: 3
Inhibition of endocannabinoid degradation rectifies motivational and dopaminergic deficits in the Q175 mouse model of Huntington’s disease
Dan P. Covey, Hannah M. Dantrassy, Samantha E. Yohn, et al.
Neuropsychopharmacology (2018) Vol. 43, Iss. 10, pp. 2056-2063
Open Access | Times Cited: 30
Endocannabinoid CB1 receptor activation upon global ischemia adversely impact recovery of reward and stress signaling molecules, neuronal survival and behavioral impulsivity
Megan Dunbar Knowles, Patricia B. de la Tremblaye, Idu Azogu, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2015) Vol. 66, pp. 8-21
Closed Access | Times Cited: 29
Cannabinoid receptors as therapeutic targets for autoimmune diseases: where do we stand?
Elaine D. Gonçalves, Rafael C. Dutra
Drug Discovery Today (2019) Vol. 24, Iss. 9, pp. 1845-1853
Closed Access | Times Cited: 29
Distinctive Evidence Involved in the Role of Endocannabinoid Signalling in Parkinson’s Disease: A Perspective on Associated Therapeutic Interventions
Tapan Behl, Gagandeep Kaur, Simona Bungău, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 17, pp. 6235-6235
Open Access | Times Cited: 27
Paradoxical kinesia may no longer be a paradox waiting for 100 years to be unraveled
Liana Melo-Thomas, Rainer K.W. Schwarting
Reviews in the Neurosciences (2023) Vol. 34, Iss. 7, pp. 775-799
Open Access | Times Cited: 8
The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia
Estefanía Rojo-Bustamante, Miguel Angel Abellanas, Pedro Clavero, et al.
Neurobiology of Disease (2018) Vol. 118, pp. 64-75
Closed Access | Times Cited: 25
Page 1 - Next Page

Scroll to top